117 related articles for article (PubMed ID: 7997539)
1. Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose.
Boland GW; Goldberg MA; Lee MJ; Mayo-Smith WW; Dixon J; McNicholas MM; Mueller PR
Radiology; 1995 Jan; 194(1):131-4. PubMed ID: 7997539
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography.
Erasmus JJ; Patz EF; McAdams HP; Murray JG; Herndon J; Coleman RE; Goodman PC
AJR Am J Roentgenol; 1997 May; 168(5):1357-60. PubMed ID: 9129444
[TBL] [Abstract][Full Text] [Related]
3. [Positron emission tomography (PET) with fludeoxyglucose F 18 in the study of adrenal masses: comparison of benign and malignant lesions].
Maurea S; Mainolfi C; Wang H; Varrella P; Panico MR; Klain M; Rossi R; Cremona F; Bazzicalupo L; Salvatore M
Radiol Med; 1996 Dec; 92(6):782-7. PubMed ID: 9122472
[TBL] [Abstract][Full Text] [Related]
4. Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F-18]fluoro-2-deoxy-D-glucose.
Dehdashti F; Siegel BA; Griffeth LK; Fusselman MJ; Trask DD; McGuire AH; McGuire DJ
Radiology; 1996 Jul; 200(1):243-7. PubMed ID: 8657920
[TBL] [Abstract][Full Text] [Related]
5. Detection of malignancies with SPECT versus PET, with 2-[fluorine-18]fluoro-2-deoxy-D-glucose.
Martin WH; Delbeke D; Patton JA; Sandler MP
Radiology; 1996 Jan; 198(1):225-31. PubMed ID: 8539384
[TBL] [Abstract][Full Text] [Related]
6. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET).
Duhaylongsod FG; Lowe VJ; Patz EF; Vaughn AL; Coleman RE; Wolfe WG
J Thorac Cardiovasc Surg; 1995 Jul; 110(1):130-9; discussion 139-40. PubMed ID: 7609536
[TBL] [Abstract][Full Text] [Related]
7. 18F-FDG PET in evaluation of adrenal lesions in patients with lung cancer.
Kumar R; Xiu Y; Yu JQ; Takalkar A; El-Haddad G; Potenta S; Kung J; Zhuang H; Alavi A
J Nucl Med; 2004 Dec; 45(12):2058-62. PubMed ID: 15585482
[TBL] [Abstract][Full Text] [Related]
8. Salivary gland tumors: pretherapy evaluation with PET.
Keyes JW; Harkness BA; Greven KM; Williams DW; Watson NE; McGuirt WF
Radiology; 1994 Jul; 192(1):99-102. PubMed ID: 8208973
[TBL] [Abstract][Full Text] [Related]
9. Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose.
Gupta NC; Frank AR; Dewan NA; Redepenning LS; Rothberg ML; Mailliard JA; Phalen JJ; Sunderland JJ; Frick MP
Radiology; 1992 Aug; 184(2):441-4. PubMed ID: 1620844
[TBL] [Abstract][Full Text] [Related]
10. Positron emission tomography, bronchogenic carcinoma, and the adrenals.
Lamki LM
AJR Am J Roentgenol; 1997 May; 168(5):1361-2. PubMed ID: 9129445
[No Abstract] [Full Text] [Related]
11. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning.
Patz EF; Lowe VJ; Hoffman JM; Paine SS; Burrowes P; Coleman RE; Goodman PC
Radiology; 1993 Aug; 188(2):487-90. PubMed ID: 8327702
[TBL] [Abstract][Full Text] [Related]
12. 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation.
Stollfuss JC; Glatting G; Friess H; Kocher F; Berger HG; Reske SN
Radiology; 1995 May; 195(2):339-44. PubMed ID: 7724750
[TBL] [Abstract][Full Text] [Related]
13. Imaging of adrenal tumors using FDG PET: comparison of benign and malignant lesions.
Maurea S; Mainolfi C; Bazzicalupo L; Panico MR; Imparato C; Alfano B; Ziviello M; Salvatore M
AJR Am J Roentgenol; 1999 Jul; 173(1):25-9. PubMed ID: 10397094
[TBL] [Abstract][Full Text] [Related]
14. FDG-PET evaluation of indeterminate pancreatic masses.
Ho CL; Dehdashti F; Griffeth LK; Buse PE; Balfe DM; Siegel BA
J Comput Assist Tomogr; 1996; 20(3):363-9. PubMed ID: 8626891
[TBL] [Abstract][Full Text] [Related]
15. Utility of PET/CT in differentiating benign from malignant adrenal nodules in patients with cancer.
Vikram R; Yeung HD; Macapinlac HA; Iyer RB
AJR Am J Roentgenol; 2008 Nov; 191(5):1545-51. PubMed ID: 18941099
[TBL] [Abstract][Full Text] [Related]
16. PET evaluation of soft-tissue masses with fluorine-18 fluoro-2-deoxy-D-glucose.
Griffeth LK; Dehdashti F; McGuire AH; McGuire DJ; Perry DJ; Moerlein SM; Siegel BA
Radiology; 1992 Jan; 182(1):185-94. PubMed ID: 1727280
[TBL] [Abstract][Full Text] [Related]
17. Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET.
Shulkin BL; Thompson NW; Shapiro B; Francis IR; Sisson JC
Radiology; 1999 Jul; 212(1):35-41. PubMed ID: 10405717
[TBL] [Abstract][Full Text] [Related]
18. The value of 18F-FDG PET-CT and 131I-norcholesterol scintigraphy in the characterization of high-risk adrenal masses.
Riaz S; Syed R; Aziz TA; Alnaim A; Chung TT; Wan S; Kurzawinski TR; Bomanji J
Nucl Med Commun; 2020 Mar; 41(3):189-195. PubMed ID: 31895761
[TBL] [Abstract][Full Text] [Related]
19. Untreated lung cancer: quantification of systematic distortion of tumor size and shape on non-attenuation-corrected 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET scans.
Zasadny KR; Kison PV; Quint LE; Wahl RL
Radiology; 1996 Dec; 201(3):873-6. PubMed ID: 8939245
[TBL] [Abstract][Full Text] [Related]
20. Pheochromocytomas that do not accumulate metaiodobenzylguanidine: localization with PET and administration of FDG.
Shulkin BL; Koeppe RA; Francis IR; Deeb GM; Lloyd RV; Thompson NW
Radiology; 1993 Mar; 186(3):711-5. PubMed ID: 8430179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]